Positive news concerning the pharmaceutical product Kaliumklorid EQL Pharma
The pharmaceutical product Kaliumklorid EQL Pharma (potassium chloride tablets) has today been approved by the Danish Medicines Agency within the framework of a so-called decentralized procedure (a common approval procedure used when more than one country is involved). National approvals for Sweden, Denmark, Norway and Finland are expected within approximately a month.
Kaliumklorid EQL Pharma belongs to a group of medicines called minerals. Potassium chloride is given to patients with low levels of potassium in the blood. It can also be given preventively in diuretic treatment.
The total turnover in the four Nordic markets is approximately 140 MSEK annually. Currently there is one generic competitor on the market in addition to the original Kaleorid® (LEO Pharma). EQL Pharma aims to start selling the product by Q1 2018 at the latest.
"We are very pleased that yet another of our niche generics has now been approved and is approaching marketing authorisation. The product is part of our long-term commitment to develop and market new strategic niche generics with little or no competition," says Christer Fåhraeus, CEO of EQL Pharma.
For further information, please contact:
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
This information is information which EQL Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on May 9, 2017.
EQL Pharma AB (publ) in short
EQL Pharma is specialized in developing and selling generic medicines, i.e. medines that are medically equivalent to the originals. The company currently markets five niche generics in the Swedish and Danish markets, in addition to these, there are a significant pipeline of additional niche generics for launch in 2017 and onwards. The business is currently entirely focused on prescription drugs in the Nordic region. EQL Pharma is based in Lund, employs 7 (8) people and is listed on AktieTorget. The company conducts extensive development of generics in cooperation with leading contract manufacturers and major pharmaceutical companies in countries including India and China.